Deciding on a fully integrated insulin pump system?

References

*Taking a bolus 15 – 20 minutes before a meal helps to keep blood sugar levels under control after eating.
^† Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off.
^§ Refers to SmartGuard^™ feature. Individual results may vary.
^Φ For a list of compatible devices, visit http://bit.ly/CheckDevices.
** Fingersticks required in manual mode and to enter SmartGuard^™. If symptoms don’t match alerts and readings, use a fingerstick. Refer to user guide. Pivotal trial participants spend avg of > 93% in SmartGuard^™.

1. General Pump Pathway Program

• Customers with more than six months remaining on their warranty are eligible for the Pathway Program.
• The Pump Pathway Program is for pump upgrades only.
• A $399 payment will be required upfront to utilize the Pump Pathway Program. The Program price includes one (1) insulin pump. CGM products and consumables are not included.
• The Pump Pathway Program does not extend the warranty period of the replaced product. The customer’s current warranty timeline will not change by purchasing a pump through this program.
• MiniMed™ pumps have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your Healthcare Provider regarding indications for use.
• Customers should verify that their insurance provider will support transitioning to the new pump, as it could affect ongoing coverage of their future pump supplies.
• Customers must return their old pump within 30 days. Customers who do not return their pump will be charged $3,200.
• Medicare customers within the 13-month rental period on a MiniMed™ 630G or MiniMed ™ 670G can participate in this program.
• An ABN will be required to utilize the Pathway program if the Medicare customer is within a 13-month rental period and transitioning from one pump to another.
• Customer agrees that the amount paid to Medtronic is commercially reasonable considering the approximate value of the exchanged pump, the price of the new pump, and the relationship between the parties.
• Customer agrees to fully and accurately report in submissions to federal healthcare programs all discounts provided by Medtronic and, upon request by the Secretary of the U.S. Department of Health and Human Services or state agency, make available information any information that Medtronic may provide concerning the discount.
• A valid prescription will be required to purchase a new pump. Other restrictions may apply.
• Pricing, terms, and conditions are subject to change at any time and without notice.

2. Competitor Continuous Glucose Monitor (CGM) Pathway Program

• The Competitor Continuous Glucose Monitor (CGM) Pathway Program is for Competitor CGM upgrades only. CGM transmitters and sensors are included with this transaction.
• Customers must have an in-warranty transmitter to participate in the Competitor Continuous Glucose Monitor (CGM) Pathway Program.
• Customers transitioning from a Competitor CGM will pay $100 out-of-pocket to purchase a Medtronic CGM transmitter and one (1) 5-pack of sensors.
• Customers must return their old transmitter within 30 days. Customers who do not return their CGM will be charged $200.
• Upon completion of the transaction, customers will receive one (1) transmitter that is compatible with their current therapy regimen and one (1) 5-pack of sensors.
• This program is available to customers whose payers bill transmitters and sensors separately. Customers whose payers utilize a monthly CGM supply allowance are excluded from this program.
• Customers using disposable CGM systems like Freestyle Libre are not eligible for the Competitor CGM Pathway Program.
• The Competitor CGM Pathway Program does not extend the warranty period of the replaced product. The customer’s current warranty timeline will not change by purchasing a CGM through this program.
• MiniMed™ CGM's have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your Healthcare Provider regarding indications for use.
• Customers should verify that their insurance provider will support transitioning to the new CGM, as it could affect ongoing coverage of their future CGM supplies.
• Customer agrees that the amount paid to Medtronic is commercially reasonable considering the approximate value of the exchanged CGM, the price of the new CGM, and the relationship between the parties.
• Customer agrees to fully and accurately report in submissions to federal healthcare programs all discounts provided by Medtronic and, upon request by the Secretary of the U.S. Department of Health and Human Services or state agency, make available information any information that Medtronic may provide concerning the discount.
• A valid prescription will be required to obtain a new CGM. Other restrictions may apply.
• Program terms and conditions are subject to change at any time and without notice.

Important safety information: MiniMed^™ 780G system with SmartGuard^™ technology with Guardian^™ 4 sensor

The MiniMed^™ 780G system is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus in persons seven years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed^™ 780G system includes SmartGuard^™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the sensor glucose (SG) value falls below or is predicted to fall below predefined threshold values.

The Medtronic MiniMed^™ 780G system consists of the following devices: MiniMed^™ 780G insulin pump, the Guardian^™ 4 transmitter, the Guardian^™ 4 sensor, One-press serter, the Accu-Chek^™ Guide Link blood glucose meter, and the Accu-Chek^™ Guide test strips. The system requires a prescription from a healthcare professional.

The Guardian^™ 4 sensor is intended for use with the MiniMed^™ 780G system and the Guardian 4 transmitter to monitor glucose levels for the management of diabetes. The sensor is intended for single use and requires a prescription. The Guardian^™ 4 sensor is indicated for up to seven days of continuous use.

The Guardian^™ 4 sensor is not intended to be used directly to make therapy adjustments while the MiniMed^™ 780G is operating in manual mode. All therapy adjustments in manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian^™ 4 sensor. The Guardian^™ 4 sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Guardian^™ 4 sensor in the abdomen or other body sites including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.

WARNING: Do not use the SmartGuard^™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard^™ feature.

WARNING: Do not use the MiniMed^™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed^™ 780G system.

WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard^™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a BG meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.

Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed^™ 780G system has not been studied in pregnant women, persons with type 2 diabetes, or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library